Low-density lipoprotein receptor variants are associated with spontaneous and treatment-induced recovery from hepatitis C virus infection

Infection, Genetics and Evolution

Volumn 9, Issue 5, 2009, Pages 847-852

  Mas Marques, Andreas ^a   Mueller, Tobias ^b   Welke, Justus ^a,b   Taube, Stefan ^a   Sarrazin, Christoph ^c   Wiese, Manfred ^d   Halangk, Juliane ^b   Witt, Heiko ^b   Ahlenstiel, Golo ^e   Spengler, Ulrich ^e   Goebel, Uwe ^f   Schott, Eckart ^b   Weich, Viola ^b   Schlosser, Beate ^b   Wasmuth, Hermann E ^g   Lammert, Frank ^h   Berg, Thomas ^b   Schreier, Eckart ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d Klinikum St Georg   (Germany)

^e UNIVERSITY OF BONN   (Germany)

^f CARL THIEM KLINIKUM   (Germany)

^g UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^h SAARLAND UNIVERSITY   (Germany)

Author keywords

Antiviral therapy; HCV infection; Interferon; LDL receptor; LDLR; Ribavirin; Self limited infection; Single nucleotide alteration; Spontaneous recovery; Virologic response

Indexed keywords

ADENINE; ALPHA INTERFERON; GUANINE; LOW DENSITY LIPOPROTEIN RECEPTOR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DOSE RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN VARIANT; VIROLOGY;

3' UNTRANSLATED REGIONS; ADULT; AGED; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; EXONS; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, LDL; REMISSION INDUCTION; REMISSION, SPONTANEOUS; YOUNG ADULT;

HEPATITIS C VIRUS;

EID: 67651085278     PISSN: 15671348     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.meegid.2009.05.002     Document Type: Article

References (23)

1. Agnello V., Abel G., Elfahal M., Knight G.B., and Zhang Q.X. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 12766-12771
2. Akuta N., Suzuki F., Kawamura Y., Yatsuji H., Sezaki H., Suzuki Y., Hosaka T., Kobayashi M., Kobayashi M., Arase Y., Ikeda K., and Kumada H. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J. Hepatol. 46 (2007) 403-410
3. Andre P., Komurian-Pradel F., Deforges S., Perret M., Berland J.L., Sodoyer M., Pol S., Brechot C., Paranhos-Baccala G., and Lotteau V. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J. Virol. 76 (2002) 6919-6928
4. Berg T., Sarrazin C., Herrmann E., Hinrichsen H., Gerlach T., Zachoval R., Wiedenmann B., Hopf U., and Zeuzem S. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 37 (2003) 600-609
5. Carriere M., Rosenberg A.R., Conti F., Chouzenoux S., Terris B., Sogni P., Soubrane O., Calmus Y., and Podevin P. Low density lipoprotein receptor transcripts correlates with liver hepatitis C virus RNA in patients with alcohol consumption. J. Viral. Hepat. 13 (2006) 633-642
6. Chen J.M., Ferec C., and Cooper D.N. A systematic analysis of disease-associated variants in the 3' regulatory regions of human protein-coding genes II: the importance of mRNA secondary structure in assessing the functionality of 3′ UTR variants. Hum. Genet. 120 (2006) 301-333
7. Gudnason V., Patel D., Sun X.M., Humphries S., Soutar A.K., and Knight B.L. Effect of the StuI polymorphism in the LDL receptor gene (Ala 370 to Thr) on lipid levels in healthy individuals. Clin. Genet. 47 (1995) 68-74
8. Helle F., and Dubuisson J. Hepatitis C virus entry into host cells. Cell Mol. Life Sci. 65 (2008) 100-112
9. Hennig B.J., Hellier S., Frodsham A.J., Zhang L., Klenerman P., Knapp S., Wright M., Thomas H.C., Thursz M., and Hill A.V. Association of low-density lipoprotein receptor polymorphisms and outcome of hepatitis C infection. Genes Immun. 3 (2002) 359-367
10. Höhne M., Schreier E., and Roggendorf M. Sequence variability in the env-coding region of hepatitis C virus isolated from patients infected during a single source outbreak. Arch. Virol. 137 (1994) 25-34
11. Molina S., Castet V., Fournier-Wirth C., Pichard-Garcia L., Avner R., Harats D., Roitelman J., Barbaras R., Graber P., Ghersa P., Smolarsky M., Funaro A., Malavasi F., Larrey D., Coste J., Fabre J.M., Sa-Cunha A., and Maurel P. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J. Hepatol. 46 (2007) 411-419
12. Monazahian M., Bohme I., Bonk S., Koch A., Scholz C., Grethe S., and Thomssen R. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J. Med. Virol. 57 (1999) 223-229
13. Muallem H., North K.E., Kakoki M., Wojczynski M.K., Li X., Grove M., Boerwinkle E., Wilhelmsen K.C., Heiss G., and Maeda N. Quantitative effects of common genetic variations in the 3′UTR of the human LDL-receptor gene and their associations with plasma lipid levels in the Atherosclerosis Risk in Communities study. Hum. Genet. (2007)
14. Mueller T., Mas-Marques A., Sarrazin C., Wiese M., Halangk J., Witt H., Ahlenstiel G., Spengler U., Goebel U., Wiedenmann B., Schreier E., and Berg T. Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection. J. Hepatol. 41 (2004) 652-658
15. Petit J.M., Minello A., Duvillard L., Jooste V., Monier S., Texier V., Bour J.B., Poussier A., Gambert P., Verges B., and Hillon P. Cell surface expression of LDL-receptor in chronic hepatitis C: correlation with viral load. Am. J. Physiol. Endocrinol. Metab. (2007)
16. Poynard T., Ratziu V., McHutchison J., Manns M., Goodman Z., Zeuzem S., Younossi Z., and Albrecht J. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 38 (2003) 75-85
17. Trepo C. Genotype and viral load as prognostic indicators in the treatment of hepatitis C. J. Viral Hepat. 7 (2000) 250-257
18. Westin J., Lagging M., Dhillon A.P., Norkrans G., Romero A.I., Pawlotsky J.M., Zeuzem S., Schalm S.W., Verheij-Hart E., Negro F., Missale G., Neumann A.U., and Hellstrand K. Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. J. Viral Hepat. 14 (2007) 29-35
19. Wiese M., Grungreiff K., Guthoff W., Lafrenz M., Oesen U., and Porst H. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany-a 25-year multicenter study. J. Hepatol. 43 (2005) 590-598
20. Wunschmann S., Muller H.M., Stipp C.S., Hemler M.E., and Stapleton J.T. In vitro interaction between hepatitis C virus (HCV) envelope glycoprotein E2 and serum lipoproteins (LPs) results in enhanced cellular binding of both HCV E2 and LPs. J. Infect. Dis. 194 (2006) 1058-1067
21. Yamaki E., Hirayama T., Wu L.L., Hopkins P.N., Williams R.R., and Emi M. Molecular genetic diagnosis of a family with hypercholesterolemia by a mismatched PCR-RFLP method for genotyping single base substitution of the LDL receptor gene. Jpn. Heart J. 39 (1998) 681-686
22. Zhao L.J., Zhang X.L., Zhao P., Cao J., Cao M.M., Zhu S.Y., Liu H.Q., and Qi Z.T. Up-regulation of ERK and p38 MAPK signaling pathways by hepatitis C virus E2 envelope protein in human T lymphoma cell line. J. Leukoc. Biol. 80 (2006) 424-432
23. Zhao L.J., Zhao P., Chen Q.L., Ren H., Pan W., and Qi Z.T. Mitogen-activated protein kinase signalling pathways triggered by the hepatitis C virus envelope protein E2: implications for the prevention of infection. Cell Prolif. 40 (2007) 508-521